Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Nat Med. 2012 Nov 25;18(12):1827–1834. doi: 10.1038/nm.3013

Figure 4. NK depletion enhances oHSV efficacy.

Figure 4

(a) Viral titers as a function of NK cell depletion, 72 hours after rQNestin34.5 inoculation into athymic mice bearing U87dEGFR glioma (n = 4–5/group). (b) Kaplan-Meier survival curves for athymic mice bearing U87dEGFR tumors treated with rQNestin34.5 vs. vehicle as a function of NK cell depletion (with antibody to either asialo-GM1 or TMβ1) (n = 5/group). (c, d) Kaplan-Meier survival curves for the syngeneic 4C8 mouse glioblastoma model. NK depletion was carried out with TMβ1 specific antibody (c) or NK1.1 specific antibody (d) prior to rQNestin34.5 or vehicle inoculation into brain tumors (n = 8–14/group). (e, f) Differences in gene expression of 84 mouse inflammatory genes, in the presence (e) or absence (f) of NK cells, 72 hours after intracranial inoculation of rQNestin34.5 into athymic mice bearing U87dEGFR cells (n = 4–5/group). Each row and column is represented by a unique number denoting a different transcript. The identity of the transcript following tumor treatment is listed in Supplementary tables 2a (for vehicle vs rQNestin34.5 treatment) and 2b (for asialo-GM1+rQNestin34.5 vs. rQNestin34.5 treatment). * P < 0.05; ** P < 0.01; *** P < 0.001. Error bars represent +/− standard deviation.